Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

$3 million grant from the Gates Foundation for tuberculosis vaccine research

26.08.2009
TuBerculosis Vaccine Initiative (TBVI) recently received a $3million grant for a three year term from the Bill & Melinda Gates Foundation. This grant enables the nonprofit organization to strengthen its fundraising and communication activities in order to increase awareness and support for tuberculosis (TB) vaccine research and raise funds for the development of safer and more effective vaccines.

In the coming 10 years TBVI hopes to raise 200 million euros from governments, foundations and private industry for the discovery and early clinical development of new vaccines. Development of new vaccines is crucial because the only existing vaccine, BCG, is not very effective in young adults, the group of people mostly affected by the disease.

“New vaccines are essential to achieve the international aim of a TB-free world in 2050. We need several types, not only for initial protection against TB, but also to boost adolescent immunity and prevent disease in latently infected individuals,” explains Jelle Thole, director of TBVI. “To enable development of these vaccines, more investment is needed.”

TBVI financially and practically supports and facilitates a growing international network of over thirty universities, institutes and industries involved in research and development of new TB vaccines. The organization evolved from TBVAC, a European Union (EU) funded project to identify good candidates for new TB vaccines. TBVAC has yielded five new TB vaccine candidates, fifteen candidate biomarkers and three candidate adjuvant molecules. These hopeful candidates are now in preclinical development or even clinical phase.

TBVI is extremely pleased with the encouraging new signs of progress on TB. “Because of this funding, we can continue to change new discoveries into real vaccines,” says Joris Vandeputte, senior vice president Fundraising & Advocacy at TBVI. “These vaccines are urgently needed, as the resurrection of TB is a ticking time bomb. Many people believe it is a disease of the past, but in fact it is endangering our future, taking almost 1.8 million lives a year.”

The global burden of TB is slowly falling, but still two billion people, about one third of the world’s population, are estimated to be infected with the mycobacteria that cause TB. Most of them develop a latent infection, with about a 10 percent risk of developing the infectious disease later in life. People with HIV are 20 times more likely to develop the symptoms once they are infected. Efficient drugs to treat TB are available, but involve a long and burdensome treatment period of up to a year. Additionally, worldwide prevalence of various forms of drug-resistant TB poses an increasing problem and enormous challenges to effective treatment.

With new infections occurring at a rate of one per second, millions of people develop TB symptoms every year. In 2007, there were 9.27 million new cases. 500,000 of those were multi-drug resistant and 50,000 of those were extensively drug resistant (source: World Health Organization).

Jac Niessen | alfa
Further information:
http://www.wur.nl
http://www.tbvi.eu

More articles from Awards Funding:

nachricht Scientist at Kiel University receive EU funding to develop new implantats
22.11.2017 | Christian-Albrechts-Universität zu Kiel

nachricht Tracking down the origins of gold
08.11.2017 | Heidelberger Institut für Theoretische Studien gGmbH

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Underwater acoustic localization of marine mammals and vehicles

23.11.2017 | Information Technology

Enhancing the quantum sensing capabilities of diamond

23.11.2017 | Physics and Astronomy

Meadows beat out shrubs when it comes to storing carbon

23.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>